Note: This document contains side effect information about pazopanib. Some of the dosage forms listed on this page may not apply to the brand name Votrient.
Common side effects of Votrient include: bleeding tendency disorder, abdominal pain, decreased serum glucose, decreased serum magnesium, decreased serum phosphate, diarrhea, fatigue, hypertension, increased serum alanine aminotransferase, increased serum aspartate aminotransferase, increased serum bilirubin, leukopenia, nausea, neutropenia, thrombocytopenia, vomiting, and anorexia. Other side effects include: hypothyroidism, and proteinuria. See below for a comprehensive list of adverse effects.
Applies to pazopanib: oral tablet
Oral route (Tablet)
Severe and fatal hepatotoxicity has occurred during clinical trials. Monitor hepatic function in all patients. Interrupt, reduce, or discontinue treatment as recommended.
Along with its needed effects, pazopanib (the active ingredient contained in Votrient) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor immediately if any of the following side effects occur while taking pazopanib:
Some side effects of pazopanib may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
Applies to pazopanib: oral tablet
-ALT and AST elevations occurred early in the treatment course; 92.5% of all transaminase elevations of any grade occurred in the first 18 weeks.
-Hepatic failure was the cause of death for 0.2% of RCC patients and 0.4% of STS patients.
Very common (10% or more): Increased ALT (up to 53%), increased AST (up to 53%), increased total bilirubin (up to 36%), increased alkaline phosphatase (up to 32%)
Common (1% to 10%): Abnormal hepatic function, hepatotoxicity, decreased alkaline phosphatase, increased gamma-glutamyltransferase (GGT), abnormal liver function test
Uncommon (0.1% to 1%): Jaundice, drug-induced liver injury, hepatic failure, increased hepatic enzyme
Postmarketing reports: Increased GGT
-A majority of the patients with myocardial dysfunction had concurrent hypertension which may have exacerbated cardiac dysfunction in patients at risk possibly by increasing cardiac afterload.
-Cardiac dysfunction included left ventricular dysfunction, cardiac failure, and restrictive cardiomyopathy.
-Venous thromboembolic events included deep vein thrombosis, pulmonary embolism, and thrombosis terms.
Very common (10% or more): Hypertension (up to 42%), myocardial dysfunction (up to 11%), chest pain (up to 10%)
Common (1% to 10%): Venous thromboembolic events, cardiac dysfunction, bradycardia, QT prolongation, myocardial infarction or ischemia, hot flush, flushing
Uncommon (0.1% to 1%): Torsades de pointes, congestive heart failure, fatal arterial thromboembolic events, hypertensive crisis
Very common (10% or more): Tumor pain (up to 32%), hemorrhagic events (up to 13%)
Common (1% to 10%): Edema, epistaxis, mouth ulceration, dry mouth, mucosal inflammation, gingival infection, hiccups
Uncommon (0.1% to 1%): Fatal hemorrhage, cerebral/intracranial hemorrhage, infections (with or without neutropenia), infectious peritonitis, menorrhagia, metrorrhagia, oropharyngeal pain
Postmarketing reports: Infections (with or without neutropenia)
-RCC: The most common hemorrhagic events were hematuria, epistaxis, hemoptysis, and rectal hemorrhage.
-STS: The most common hemorrhagic events were epistaxis, mouth hemorrhage, and anal hemorrhage.
-Edema events included peripheral edema, eye edema, localized edema, and face edema.
-TMA included thrombotic thrombocytopenic purpura (TTP) and hemolytic uremic syndrome (HUS).
Very common (10% or more): Increased creatinine (up to 26%), proteinuria (up to 12%)
Common (1% to 10%): Increased urea
Uncommon (0.1% to 1%): Nephrotic syndrome, thrombotic microangiopathy (TMA)
Postmarketing reports: Thrombotic microangiopathy (TMA)
Very common (10% or more): Diarrhea (up to 59%), nausea (up to 56%), vomiting (up to 33%), gastrointestinal pain (up to 23%), abdominal pain (up to 14%), mucositis (up to 12%), stomatitis (up to 11%)
Common (1% to 10%): Dyspepsia, flatulence, abdominal distension
Uncommon (0.1% to 1%): Perforation or fistula, fatal perforations, hematochezia, melena, frequent bowel movements, hematemesis, pancreatitis, peritonitis
Postmarketing reports: Pancreatitis, flatulence
Very common (10% or more): Fatigue (up to 65%), dysgeusia (up to 28%), headache (up to 23%), dizziness (up to 11%)
Common (1% to 10%): Insomnia, dysphonia, lethargy, paresthesia, peripheral sensory neuropathy, chills
Uncommon (0.1% to 1%): Hypoesthesia, somnolence, mucous membrane disorder, cerebral infarction, transient ischemic attack, cerebrovascular accident, ischemic stroke, posterior reversible encephalopathy syndrome/reversible posterior leukoencephalopathy syndrome (PRES/RPLS)
Postmarketing reports: PRES/RPLS
-Dysgeusia included ageusia and hypogeusia.
Common (1% to 10%): Hypothyroidism, increased thyroid stimulating hormone
Uncommon (0.1% to 1%): Abnormal thyroid function test
-Renal cell carcinoma (RCC): The most commonly observed adverse reactions (20% or more) were diarrhea, hypertension, hair color change, nausea, fatigue, anorexia, and vomiting.
-Soft tissue sarcoma (STS): The most commonly observed adverse reactions (20% or more) were fatigue, diarrhea, nausea, decreased weight, hypertension, decreased appetite, vomiting, tumor pain, hair color changes, musculoskeletal pain, headache, dysgeusia, dyspnea, and skin hypopigmentation.
Very common (10% or more): Hair color changes (up to 39%), skin hypopigmentation (up to 21%), exfoliative rash (up to 18%), palmar-plantar erythrodysesthesia syndrome (up to 18%), alopecia (up to 12%), rash (up to 11%)
Common (1% to 10%): Dry skin, skin depigmentation, nail disorder, pruritus, erythema, hyperhidrosis
Uncommon (0.1% to 1%): Skin exfoliation, photosensitivity reaction, erythematous rash, skin disorder, macular rash, pruritic rash, vesicular rash, papular rash, skin ulcer
Common (1% to 10%): Hematuria
Very common (10% or more): Leukopenia (up to 44%), lymphocytopenia (up to 43%), thrombocytopenia (up to 36%), neutropenia (up to 34%), anemia (up to 27%)
Common (1% to 10%): Decreased white blood cell count
Uncommon (0.1% to 1%): Decreased platelet count
Very common (10% or more): Decreased weight (up to 48%), increased glucose (up to 45%), decreased appetite (up to 40%), increased albumin (up to 34%), decreased albumin (up to 34%), decreased phosphorus (up to 34%), decreased calcium (up to 33%), decreased sodium (up to 31%), increased potassium (up to 27%), decreased magnesium (up to 26%), anorexia (up to 22%), decreased glucose (up to 17%)
Common (1% to 10%): Increased lipase, increased amylase, dehydration, abnormal blood cholesterol
Very common (10% or more): Musculoskeletal pain (up to 23%), myalgia (up to 23%), asthenia (up to 14%)
Common (1% to 10%): Arthralgia, muscle spasms
Common (1% to 10%): Blurred vision
Uncommon (0.1% to 1%): Eyelash discoloration
Frequency not reported: Increased toxicity and mortality with other cancer therapies
-Fatal toxicities including pulmonary hemorrhage, gastrointestinal hemorrhage, and sudden death have occurred when used with other cancer agents.
Very common (10% or more): Dyspnea (up to 20%), cough (up to 17%)
Common (1% to 10%): Pneumothorax
Uncommon (0.1% to 1%): Rhinorrhea
Medically reviewed by BestRx Medical Team Last updated on 1/1/2020.
Source: Drugs.com Votrient